Several clinical studies evaluating asciminib in frontline CML therapy are currently ongoing (e.g., ASCI4FIRST, ASCI4START, ASCEND), with promising preliminary results indicating superior efficacy, improved tolerability, and a lower rate of treatment discontinuation due to toxicity compared to ATP-competitive inhibitors However, clinical trials of asciminib in both advanced-line and first-line CML treatment also report the emergence of resistance, often due to acquired or persisting mutations in BCR::ABL1 [2, 4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.